Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

BLCO Bausch + Lomb Corp.

Watchlist
15.500
-0.010-0.06%
Close 08/08 16:00 ET
15.50000.00%
Post Mkt Price 08/08 16:00 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
15.940
Open
15.590
Turnover
15.49M
Low
15.310
Pre Close
15.510
Volume
993.84K
Market Cap
5.42B
P/E(TTM)
39.85
52wk High
20.200
Shares
350.00M
P/E(Static)
29.81
52wk Low
12.200
Float Cap
542.50M
Bid/Ask %
-100.00%
Historical High
20.200
Shs Float
35.00M
Volume Ratio
0.54
Historical Low
12.200
Dividend TTM
--
Div Yield TTM
--
P/B
0.79
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
2.84%
Amplitude
4.06%
Avg Price
15.583
Lot Size
1
Float Cap
542.50M
Bid/Ask %
-100.00%
Historical High
20.200
Shs Float
35.00M
Volume Ratio
0.54
Historical Low
12.200
Dividend TTM
--
P/B
0.79
Dividend LFY
--
Turnover Ratio
2.84%
Amplitude
4.06%
Avg Price
15.583
Lot Size
1
Price Forecast

No Data

News

Comment

No More
Company Overview More
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
CEO: Papa, Joseph C.
Market: NYSE
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top